<p> <b>Full Title</b><br> Protocol QXL138AM-001: A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma </p> <p> <b>Study Treatment</b><br> QXL138AM is interferon alpha 2 (IFNα2) masked immunocytokine (MIC) fused to antibody targeting CD138 </p> <p> <b>Eligibility/Info</b> <ul> <li><b>Solid tumors</b>: Metastatic ovarian, pancreatic, urothelial, renal, hepatocellular, gastrointestinal (GI), lung, prostate, or breast cancer that has continued to grow after standard systemic therapies.</li> <li><b>Multiple Myeloma</b>: Multiple myeloma that has continued to grow after treatment with at least 3 lines of therapy that included an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulating agent. </li> </ul> </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p>